APEIRONs respiratory drug product to start pilot clinical trial to treat coronavirus disease

APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease

06:59 EST 27 Feb 2020 | Bionity

APEIRON Biologics AG announced the launch of a Pilot investigator-initiated clinical trial (IIT) with APN01, a recombinant human angiotensin-converting enzyme 2 (rhACE2), to treat patients with severe coronavirus infection in the People's Republic of China. The randomized, unblinded trial will treat...

More From BioPortfolio on "APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease"